Monoclonal Antibodies in Veterinary Health Market Report 2026

The monoclonal antibodies in veterinary health market size has grown rapidly in recent years. It will grow from $0.92 billion in 2025 to $1.06 billion in 2026 at a compound annual growth rate (CAGR) of 15.2%. The growth in the historic period can be attributed to rising prevalence of canine cancers, increasing incidence of autoimmune disorders in pets, limited availability of targeted therapies, growth of veterinary hospitals, awareness of advanced veterinary treatments.

The monoclonal antibodies in veterinary health market size is expected to see rapid growth in the next few years. It will grow to $1.85 billion in 2030 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to technological advancements in mAb engineering, increasing adoption of species-specific therapies, rising investment in veterinary oncology and dermatology, growth of personalized veterinary medicine, expansion of global veterinary healthcare infrastructure. Major trends in the forecast period include growth in monoclonal antibody-based canine cancer treatments, rising use of mabs for autoimmune disorders in dogs, expansion of veterinary dermatology applications, increasing adoption of targeted pain management therapies, development of species-specific antibody therapies for cats, horses, and livestock.

The rising incidence of animal diseases is expected to drive the growth of the monoclonal antibodies in veterinary health market going forward. The increase in animal disease incidence is driven by intensified farming practices, which elevate the risk of infectious disease spread, and climate change, which expands the range of disease vectors such as ticks and mosquitoes. Monoclonal antibodies are highly effective for treating animal diseases as they target specific pathogens or proteins involved in disease processes, offering precise and targeted treatments. For example, in June 2024, according to a report published by GOV.UK, a UK-based government website, between April 2023 and March 2024, the number of animals slaughtered due to TB incidents rose by 5% in England to 21,298 and by 17% in Wales to 11,197. Therefore, the rising incidence of animal diseases is driving the growth of the monoclonal antibodies in veterinary health market.

Leading players in the monoclonal antibodies in veterinary health market are focusing on developing innovative veterinary therapeutic solutions, such as anti-NGF monoclonal antibody treatments to address conditions like chronic pain and inflammation in animals. Anti-NGF monoclonal antibody treatment is a therapeutic approach that targets and inhibits nerve growth factor (NGF) to reduce pain and inflammation in animals suffering from chronic conditions. For instance, in May 2023, Zoetis, a US-based animal health company, received FDA approvals for Librela (bedinvetmab injection), the first monoclonal antibody treatment for controlling pain associated with osteoarthritis (OA) in dogs, administered as a once-monthly injection, and Apoquel Chewable, the first chewable medication for managing allergic itch and inflammation in dogs aged one year or older. Librela targets and inhibits NGF, blocking pain signals from reaching the brain and thereby reducing the sensation of pain in dogs with osteoarthritis. Librela represents a major advancement in veterinary pain management, providing a novel approach to treating chronic pain in dogs.

In January 2024, Ceva Santé Animale, a France-based provider of animal health products and services, acquired Scout Bio Inc. for an undisclosed amount. This acquisition allows Ceva Santé to strengthen its global biotechnology efforts in animal health by leveraging Scout Bio's expertise in advanced therapies such as gene therapy and monoclonal antibodies, accelerating innovation to address chronic diseases in pets. Scout Bio Inc. is a US-based biotechnology company developing a pipeline of monoclonal antibody therapies for chronic conditions in pets.

Major companies operating in the monoclonal antibodies in veterinary health market are Zoetis Inc, Boehringer Ingelheim International GmbH, MSD Animal Health, Elanco Animal Health Incorporated, Heska Corporation, Ceva Santé Animale S.A., Biogénesis Bagó S.A., PetMedix Ltd, Merck & Co Inc, Virbac SA, Kindred Biosciences Inc, Dechra Pharmaceuticals, Vetigenics, Akston Biosciences Corporation, MabGenesis Inc, IDEXX Laboratories Inc, Nexvet Biopharma, Epitopix LLC, Indian Immunologicals Ltd, Vetoquinol, Phibro Animal Health, Norbrook Laboratories, AnimalCare, Eco Animal Health, Venkys, Hester Biosciences Limited, ImmuCell.

North America was the largest region in the monoclonal antibodies in veterinary health market in 2025. The regions covered in the monoclonal antibodies in veterinary health market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the monoclonal antibodies in veterinary health market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the monoclonal antibodies in veterinary health market by increasing the cost of imported biologics, laboratory equipment, and advanced reagents. Segments such as canine cancer treatments and autoimmune disorder therapies are most impacted, particularly in regions like North America and Europe that rely heavily on imports. While tariffs create cost pressures, they also encourage local production, innovation in cost-effective antibody therapies, and development of regionally optimized veterinary mAbs.

The monoclonal antibodies in veterinary health market research report is one of a series of new reports that provides monoclonal antibodies in veterinary health market statistics, including monoclonal antibodies in veterinary health industry global market size, regional shares, competitors with a monoclonal antibodies in veterinary health market share, detailed monoclonal antibodies in veterinary health market segments, market trends and opportunities, and any further data you may need to thrive in the monoclonal antibodies in veterinary health industry. This monoclonal antibodies in veterinary health market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Monoclonal antibodies in veterinary health are engineered proteins designed to target and neutralize specific pathogens or toxins in animals, assisting in the diagnosis and treatment of various diseases. They are produced by cloning a single type of immune cell to generate identical antibodies that specifically bind to their target.

Monoclonal antibodies in veterinary health are primarily used for dogs, although they can also be used for other animals. Monoclonal antibodies are applied in fields such as dermatology and pain management, with end users including veterinary hospitals and other related facilities.

The monoclonal antibodies in veterinary health market consist of sales of diagnostic kits, therapeutic drugs, research reagents, monoclonal antibody drugs, and therapeutic formulations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.